Loading...
•
Sep 30, 2022
OPKO Health Q3 2022 Earnings Report
Reported business highlights and financial results for the third quarter of 2022.
Key Takeaways
OPKO Health's Q3 2022 revenue was $179.7 million, a decrease from $385.8 million in the same period of 2021. The company experienced an operating loss of $87.8 million, compared to an operating income of $37.8 million in Q3 2021. Net loss for the quarter was $86.1 million, or $0.11 per share, a significant shift from the net income of $28.7 million, or $0.04 per diluted share, in the prior year.
Pfizer launched NGENLA® in Japan, Germany, and other global markets, awaiting pricing approvals in additional European countries and working with the FDA for U.S. approval.
ModeX Therapeutics advanced its proprietary immunotherapy pipeline.
BioReference Laboratories continued cost reduction and business rationalization efforts, reducing annualized costs by over $100 million.
OPKO Health's cash and cash equivalents totaled $180.8 million as of September 30, 2022.
Forward Guidance
OPKO Health's press release contains forward-looking statements regarding expected financial performance, market expectations for products, regulatory landscape, product launches, pricing approvals, RAYALDEE prescriptions, product development efforts, business partner relationships, commercialization of products, and ability to market and sell products in development.
Positive Outlook
- Expected financial performance
- Market expectations for products
- Product launches
- Pricing approvals
- Product development efforts
Challenges Ahead
- Downturns and a changing regulatory landscape in the highly competitive healthcare industry
- Products may not launch in all territories
- Timing of launches
- Ability to get beneficial pricing approvals
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...